Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Several factors have contributed to Lilly's share price decline, including earnings misses and increased competition. For a ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

The new research and development site will combine research, process development and clinical trial manufacturing ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...